Natera (NASDAQ:NTRA) Insider Sells $186,778.95 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 915 shares of Natera stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $204.13, for a total value of $186,778.95. Following the completion of the transaction, the insider owned 150,882 shares in the company, valued at $30,799,542.66. This trade represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, March 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $199.85, for a total value of $599,550.00.
• On Tuesday, February 3rd, Solomon Moshkevich sold 1,639 shares of Natera stock. The stock was sold at an average price of $230.77, for a total value of $378,232.03.
• On Monday, February 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $231.44, for a total value of $694,320.00.
• On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The shares were sold at an average price of $237.66, for a total transaction of $285,192.00.
• On Tuesday, January 27th, Solomon Moshkevich sold 1,013 shares of Natera stock. The shares were sold at an average price of $240.53, for a total transaction of $243,656.89.
• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The stock was sold at an average price of $235.00, for a total transaction of $68,855.00.
• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The stock was sold at an average price of $234.74, for a total transaction of $5,447,141.70.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The shares were sold at an average price of $228.95, for a total transaction of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The stock was sold at an average price of $230.76, for a total transaction of $1,082,725.92.

Natera Stock Down 1.2%

NASDAQ NTRA traded down $2.34 during trading hours on Wednesday, hitting $196.61. 1,404,465 shares of the stock were exchanged, compared to its average volume of 1,187,138. The company has a market cap of $27.87 billion, a price-to-earnings ratio of -128.50 and a beta of 1.65. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $256.36. The stock has a 50-day moving average of $221.97 and a 200 day moving average of $206.14.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The firm had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. During the same quarter last year, the firm earned ($0.41) earnings per share. On average, equities research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on NTRA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research note on Thursday, January 22nd. TD Cowen reiterated a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. Robert W. Baird raised their target price on Natera from $239.00 to $257.00 and gave the company an “outperform” rating in a report on Friday, February 27th. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Finally, Wells Fargo & Company increased their price target on shares of Natera from $205.00 to $215.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average target price of $253.47.

Institutional Investors Weigh In On Natera

A number of institutional investors and hedge funds have recently modified their holdings of NTRA. Reflection Asset Management acquired a new position in Natera during the fourth quarter worth $29,000. Palladiem LLC purchased a new position in shares of Natera in the fourth quarter valued at $31,000. Bank of Jackson Hole Trust raised its stake in shares of Natera by 103.8% during the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after buying an additional 83 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of Natera during the 4th quarter worth $39,000. Finally, Flagship Harbor Advisors LLC purchased a new stake in shares of Natera in the 4th quarter worth about $41,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.